Dokekias A E, Basseila G B
Service d'hématologie, CHU de Brazzaville, BP 13.0227RP, Brazzaville, Congo.
Transfus Clin Biol. 2010 Oct;17(4):232-41. doi: 10.1016/j.tracli.2010.06.027. Epub 2010 Oct 20.
The standard of care for major sickle cell diseases in crisis is based on blood transfusion, but this remains a risky therapy in sub-Saharan Africa. The objective of this retrospective and prospective study was to assess exchange transfusion (ET) in homozygous sickle cell disease between 1st July 2005 and 30th June 2008 at the transfusion centre of university hospital of Brazzaville. The ET technique used was manual and made of three stages: bleeding, infusion of solution, and infusion of red cell concentrate. Clinical and biological assessments were done before and after exchanges. The indication for ET were: pregnancy (19 cases); strokes (seven cases); vaso-occlusive crisis (five cases), priapism (four cases), cardiac failure (three cases) and miscellaneous (four cases), the values of hematocut in red cell blood bag between 0.55 and 0.70 (median 0.65). The median haemoglobin level before exchange was about 5.8 g/dl (4.1-7.4 g/dl), that of HbS from haemoglobin electrophoresis about 98.4 % (94.6-100 %). Before the exchanges, viral serological tests were done with the following results: two patients with HBV antigen positive and one patient antibodies to HCV. In acute situation interval between exchanges is 3 to 10 days, whereas during chronic situation is between 14 to 28 days. No major immediate complications have been observed. Clinical situation after exchange characterized by stabilization of cerebral vascular stroke and over and control of one case of priapism complications. Assessment after exchange showed the following results: medium rate of Hb level: 9.5 g/dl (an increase of 3.7 g/dl); medium percentage of HbS reduced to 46.8 % (approximately a decrease of 51.6 %). Patient's serological status to HCV changed for one patient. This study illustrates the benefit and the limitations of the transfusion exchange during sickle cell disease in sub-Saharan Africa.
重度镰状细胞病危象的标准治疗方法是以输血为基础,但在撒哈拉以南非洲地区,这仍是一种存在风险的治疗方法。这项回顾性和前瞻性研究的目的是评估2005年7月1日至2008年6月30日期间在布拉柴维尔大学医院输血中心对纯合子镰状细胞病进行的换血疗法(ET)。所采用的ET技术为手工操作,包括三个阶段:放血、溶液输注和红细胞浓缩液输注。在每次换血前后均进行了临床和生物学评估。ET的适应症包括:妊娠(19例);中风(7例);血管闭塞性危象(5例),阴茎异常勃起(4例),心力衰竭(3例)以及其他情况(4例),红细胞血袋中的血细胞比容值在0.55至0.70之间(中位数为0.65)。换血前的血红蛋白水平中位数约为5.8 g/dl(4.1 - 7.4 g/dl),血红蛋白电泳中HbS的比例约为98.4%(94.6 - 100%)。在换血前,进行了病毒血清学检测,结果如下:2例患者HBV抗原呈阳性,1例患者抗HCV抗体呈阳性。在急性情况下,换血间隔为3至10天,而在慢性情况下为14至28天。未观察到重大的即刻并发症。换血后的临床情况表现为脑血管中风得到稳定,1例阴茎异常勃起并发症得到控制。换血后的评估结果如下:血红蛋白水平的中位数为9.5 g/dl(增加了3.7 g/dl);HbS的中位数百分比降至46.8%(大约下降了51.6%)。1例患者的HCV血清学状态发生了变化。这项研究说明了撒哈拉以南非洲地区镰状细胞病换血疗法的益处和局限性。